The American–European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey

R. E. Nappi, M. L. Krychman

Research output: Contribution to journalArticle

Abstract

Vulvar and vaginal atrophy (VVA) is a common complaint in postmenopausal women and consists of a variety of symptoms and strong repercussions that negatively affect comfort during sexual activity and ultimately impact quality of life. The EU and US REVIVE surveys have detected significant barriers in health-care professional management and educational programs that prevent correct diagnosis and effective treatment. This was common in both Europe and the US, but differential behaviors and patterns could be detected after reviewing the published results. The frequency of reporting VVA symptoms was lower in European participants. However, a better knowledge that VVA is a consequence of menopause was evident in Europe, probably in relation to more frequent gynecological visits and more frequent specialist visits as a referral health-care professional. Moreover, a trend towards an improved satisfaction with management by the health-care professional was observed in Europe. European participants acknowledged a significantly higher impact of VVA symptoms on sexual intercourse and partner interaction than North American (US) participants, and both cohorts were observed to have differences between their respective VVA symptom profiles. These observations have implications in the overall concerns that participants stated with long-term VVA medication and for the optimal therapeutic approach, providing evidence to support the concept that unexplored methods to improve management of patients with VVA remain.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalClimacteric
DOIs
Publication statusAccepted/In press - Apr 18 2016

Fingerprint

Atrophy
Delivery of Health Care
Sexual Partners
Coitus
Menopause
Surveys and Questionnaires
Sexual Behavior
Referral and Consultation
Quality of Life
Therapeutics

Keywords

  • dyspareunia
  • postmenopausal women
  • REVIVE survey
  • sexual relationships
  • vaginal dryness
  • Vulvar and vaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

The American–European difference in vulvar and vaginal atrophy views : a lesson from the REVIVE Survey. / Nappi, R. E.; Krychman, M. L.

In: Climacteric, 18.04.2016, p. 1-4.

Research output: Contribution to journalArticle

@article{650658e4a700404faecf49d2a00cced1,
title = "The American–European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey",
abstract = "Vulvar and vaginal atrophy (VVA) is a common complaint in postmenopausal women and consists of a variety of symptoms and strong repercussions that negatively affect comfort during sexual activity and ultimately impact quality of life. The EU and US REVIVE surveys have detected significant barriers in health-care professional management and educational programs that prevent correct diagnosis and effective treatment. This was common in both Europe and the US, but differential behaviors and patterns could be detected after reviewing the published results. The frequency of reporting VVA symptoms was lower in European participants. However, a better knowledge that VVA is a consequence of menopause was evident in Europe, probably in relation to more frequent gynecological visits and more frequent specialist visits as a referral health-care professional. Moreover, a trend towards an improved satisfaction with management by the health-care professional was observed in Europe. European participants acknowledged a significantly higher impact of VVA symptoms on sexual intercourse and partner interaction than North American (US) participants, and both cohorts were observed to have differences between their respective VVA symptom profiles. These observations have implications in the overall concerns that participants stated with long-term VVA medication and for the optimal therapeutic approach, providing evidence to support the concept that unexplored methods to improve management of patients with VVA remain.",
keywords = "dyspareunia, postmenopausal women, REVIVE survey, sexual relationships, vaginal dryness, Vulvar and vaginal atrophy",
author = "Nappi, {R. E.} and Krychman, {M. L.}",
year = "2016",
month = "4",
day = "18",
doi = "10.3109/13697137.2016.1173026",
language = "English",
pages = "1--4",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - The American–European difference in vulvar and vaginal atrophy views

T2 - a lesson from the REVIVE Survey

AU - Nappi, R. E.

AU - Krychman, M. L.

PY - 2016/4/18

Y1 - 2016/4/18

N2 - Vulvar and vaginal atrophy (VVA) is a common complaint in postmenopausal women and consists of a variety of symptoms and strong repercussions that negatively affect comfort during sexual activity and ultimately impact quality of life. The EU and US REVIVE surveys have detected significant barriers in health-care professional management and educational programs that prevent correct diagnosis and effective treatment. This was common in both Europe and the US, but differential behaviors and patterns could be detected after reviewing the published results. The frequency of reporting VVA symptoms was lower in European participants. However, a better knowledge that VVA is a consequence of menopause was evident in Europe, probably in relation to more frequent gynecological visits and more frequent specialist visits as a referral health-care professional. Moreover, a trend towards an improved satisfaction with management by the health-care professional was observed in Europe. European participants acknowledged a significantly higher impact of VVA symptoms on sexual intercourse and partner interaction than North American (US) participants, and both cohorts were observed to have differences between their respective VVA symptom profiles. These observations have implications in the overall concerns that participants stated with long-term VVA medication and for the optimal therapeutic approach, providing evidence to support the concept that unexplored methods to improve management of patients with VVA remain.

AB - Vulvar and vaginal atrophy (VVA) is a common complaint in postmenopausal women and consists of a variety of symptoms and strong repercussions that negatively affect comfort during sexual activity and ultimately impact quality of life. The EU and US REVIVE surveys have detected significant barriers in health-care professional management and educational programs that prevent correct diagnosis and effective treatment. This was common in both Europe and the US, but differential behaviors and patterns could be detected after reviewing the published results. The frequency of reporting VVA symptoms was lower in European participants. However, a better knowledge that VVA is a consequence of menopause was evident in Europe, probably in relation to more frequent gynecological visits and more frequent specialist visits as a referral health-care professional. Moreover, a trend towards an improved satisfaction with management by the health-care professional was observed in Europe. European participants acknowledged a significantly higher impact of VVA symptoms on sexual intercourse and partner interaction than North American (US) participants, and both cohorts were observed to have differences between their respective VVA symptom profiles. These observations have implications in the overall concerns that participants stated with long-term VVA medication and for the optimal therapeutic approach, providing evidence to support the concept that unexplored methods to improve management of patients with VVA remain.

KW - dyspareunia

KW - postmenopausal women

KW - REVIVE survey

KW - sexual relationships

KW - vaginal dryness

KW - Vulvar and vaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=84964335905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964335905&partnerID=8YFLogxK

U2 - 10.3109/13697137.2016.1173026

DO - 10.3109/13697137.2016.1173026

M3 - Article

AN - SCOPUS:84964335905

SP - 1

EP - 4

JO - Climacteric

JF - Climacteric

SN - 1369-7137

ER -